UK markets closed

Nestlé S.A. (NESN.SW)

Swiss - Swiss Delayed price. Currency in CHF
Add to watchlist
92.42-0.88 (-0.94%)
At close: 05:30PM CEST
Full screen
Previous close93.30
Bid0.00 x 0
Ask92.74 x 0
Day's range92.40 - 93.26
52-week range89.52 - 112.06
Avg. volume4,127,445
Market cap242.14B
Beta (5Y monthly)0.29
PE ratio (TTM)21.85
EPS (TTM)4.23
Earnings date25 Jul 2024
Forward dividend & yield3.00 (3.25%)
Ex-dividend date22 Apr 2024
1y target est108.23

    JPMorgan double upgraded Unilever, while cutting Nestle

    JPMorgan has turned positive on Unilever (LON:ULVR), after several years of caution, but has taken a more cautious view on Nestle (SIX:NESN) as its earnings growth moderates. Unilever has instituted several changes over the past 12 months, analysts at JPMorgan said in a note dated May 23, which have soothed the bank’s concerns, including cultural change and corporate governance; market share underperformance through increased investments and execution focus; and portfolio transformation with disposals. This feeds a stronger FY24, and should give credence to Unilever is on the path to turnaround and contribute to the stock re-rating along with positive earnings revision.

  • Benzinga

    The Ozempic Diet: Nestle Launches $5 Pizza For Weight Loss Drug Users

    On Tuesday, Nestlé SA (OTC:NSRGF) (OTC:NSRGY) unveiled Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss medications and aid consumers focused on weight management. This comes amid fears among investors that food companies could see their sales suffer significantly. Related: Changing Frugal Eating Habits – How Novo Nordisk/Eli Lilly’s Weight Loss Drugs Reshaping Food Spending. The food and drink processing conglomerate says the new line includes protein, fiber, and esse


    Nestlé and Other Food Makers Cater to Wegovy, Ozempic Users

    Weight loss drugs are rising in popularity, and food companies are cooking up new ways to win over those consumers.